Best treatments for non-hodgkin lymphoma
15 products may treat non-hodgkin lymphoma, spanning FDA drug classes such as alkylating drug, purine antimetabolite, hematopoietic stem cell mobilizer. The current highest-rated option is bendeka. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 15 drugs we list for non-hodgkin lymphoma, 1 is available as lower-cost generics, spanning classes such as alkylating drug, purine antimetabolite, hematopoietic stem cell mobilizer. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for non-hodgkin lymphoma — so confirm the right choice with your prescriber.
Understanding non-hodgkin lymphoma
Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system. Because lymph tissue is found throughout the body, NHL can begin in many places, including the lymph nodes, spleen, bone marrow, and the lining of the digestive tract. It can develop from B cells, T cells, or natural killer cells, and it includes many subtypes that behave differently: some are indolent (slow-growing) and some are aggressive (fast-growing). Signs may include painless swelling of lymph nodes in the neck, armpit, or groin, along with fever, drenching night sweats, unexplained weight loss, and feeling very tired. Diagnosis typically involves a physical exam, blood tests, imaging, and a biopsy of an affected lymph node or tissue, which a pathologist examines to confirm the diagnosis and identify the subtype. Additional tests help determine the stage (how far the disease has spread, from Stage I to Stage IV). Management ranges from watchful waiting for some slow-growing cases to active treatment, planned by a team of lymphoma experts. This is general information, not medical advice.
First-line treatment
There is no single first-line treatment for NHL. According to the National Cancer Institute and the American Cancer Society, the approach depends on the specific subtype, how advanced the disease is (its stage), and the person's age, overall health, and other prognostic factors. Choosing treatment therefore begins with accurate diagnosis and subtype identification through biopsy and pathology, along with staging tests and laboratory analyses (such as immunohistochemistry and cytogenetic testing) that help guide options. Categories of treatment may include chemotherapy, radiation therapy, immunotherapy, targeted drug therapy, high-dose chemotherapy with stem cell transplant, surgery, and, for some slow-growing cases, watchful waiting. NCI states that people with NHL should have their treatment planned by a team of health care providers who are experts in treating lymphomas, and the specific plan is individualized for each patient by that oncology team. This is general information, not medical advice.
Top-rated picks for non-hodgkin lymphoma: 1. Bendeka · 2. Gleostine · 3. Mavenclad
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Injectable | Alkylating Drug | No data | — | View → | |
| 2 | 70/100 | Prescription | Capsule | Alkylating Drug | No data | — | View → | |
| 3 | 70/100 | Prescription | Tablet | Purine Antimetabolite | No data | — | View → | |
| 4 | 70/100 | Prescription | Injectable | Hematopoietic Stem Cell Mobilizer | No data | — | View → | |
| 5 | 70/100 | Prescription | Injectable | Alkylating Drug | No data | — | View → | |
| 6 | 70/100 | Prescription | Tablet | — | No data | — | View → | |
| 7 | Not yet rated | Prescription | Tablet | — | No data | — | View → | |
| 8 | Not yet rated | Prescription | Injectable | Leukocyte Growth Factor | No data | — | View → | |
| 9 | Not yet rated | Prescription | Capsule | Alkylating Drug | No data | — | View → | |
| 10 | Not yet rated | Prescription | Capsule | — | No data | — | View → |
Narrow by drug class
Explore the class hubs: alkylating drug
Full ranking · 15 treatments
bendeka
PrescriptionFDA-sourced
Bendeka (Bendamustine Hydrochloride) is an alkylating drug used to treat Lymphoid Leukemia, Non-Hodgkin Lymphoma.
Price varies
gleostine
Boxed warningPrescriptionFDA-sourced
Gleostine (Lomustine) is an alkylating drug used to treat Brain Neoplasms, Colonic Neoplasms, Hodgkin Disease, Kidney Neoplasms.
Price varies
mavenclad
Boxed warningPrescriptionFDA-sourced
Mavenclad (Cladribine) is a purine antimetabolite used to treat Hairy Cell Leukemia, Non-Hodgkin Lymphoma, Multiple Sclerosis, B-Cell Chronic Lymphocytic Leukemia.
Price varies
mozobil
PrescriptionFDA-sourced
Mozobil (Plerixafor) is a hematopoietic stem cell mobilizer used to treat Non-Hodgkin Lymphoma, Multiple Myeloma.
Price varies
vivimusta
PrescriptionFDA-sourced
Vivimusta (Bendamustine Hydrochloride) is an alkylating drug used to treat Lymphoid Leukemia, Non-Hodgkin Lymphoma.
Price varies
zydelig
PrescriptionFDA-sourced
Zydelig (Idelalisib) is a medication used to treat Lymphoid Leukemia, Non-Hodgkin Lymphoma.
Price varies
Frequently asked
- What treats non-hodgkin lymphoma?
- Our catalog lists 15 products that may treat non-hodgkin lymphoma, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is bendeka.
- What is the best-rated treatment for non-hodgkin lymphoma?
- By our independent recall-safety rating — not an efficacy measure — bendeka ranks highest among the products we list for non-hodgkin lymphoma. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat non-hodgkin lymphoma?
- Treatments for non-hodgkin lymphoma span FDA drug classes including alkylating drug, purine antimetabolite, hematopoietic stem cell mobilizer, leukocyte growth factor, lymphocyte growth factor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Sources
The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.